- Home
- WYY vs EQ Comparison
WYY vs EQ Comparison
Compare WYY & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- EQ
- Stock Information
- Founded
- WYY 1991
- EQ 2017
- Country
- WYY United States
- EQ United States
- Employees
- WYY N/A
- EQ N/A
- Industry
- WYY EDP Services
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- WYY Technology
- EQ Health Care
- Exchange
- WYY Nasdaq
- EQ Nasdaq
- Market Cap
- WYY 32.7M
- EQ 39.0M
- IPO Year
- WYY 1998
- EQ 2018
- Fundamental
- Price
- WYY $3.89
- EQ $0.70
- Analyst Decision
- WYY Strong Buy
- EQ Buy
- Analyst Count
- WYY 1
- EQ 2
- Target Price
- WYY $7.00
- EQ $5.00
- AVG Volume (30 Days)
- WYY 84.1K
- EQ 302.6K
- Earning Date
- WYY 11-13-2024
- EQ 11-19-2024
- Dividend Yield
- WYY N/A
- EQ N/A
- EPS Growth
- WYY N/A
- EQ N/A
- EPS
- WYY N/A
- EQ N/A
- Revenue
- WYY $124,237,872.00
- EQ $42,623,000.00
- Revenue This Year
- WYY $25.94
- EQ N/A
- Revenue Next Year
- WYY $13.22
- EQ N/A
- P/E Ratio
- WYY N/A
- EQ N/A
- Revenue Growth
- WYY 23.44
- EQ 26.25
- 52 Week Low
- WYY $1.65
- EQ $0.48
- 52 Week High
- WYY $4.55
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- WYY 56.14
- EQ 41.51
- Support Level
- WYY $3.57
- EQ $0.68
- Resistance Level
- WYY $4.19
- EQ $0.89
- Average True Range (ATR)
- WYY 0.17
- EQ 0.11
- MACD
- WYY 0.03
- EQ -0.03
- Stochastic Oscillator
- WYY 58.35
- EQ 12.17
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically the company generates a majority of its revenue from the United States and rest from Europe.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.